FIELD: medicine.
SUBSTANCE: method of treating obesity, type II diabetes or metabolic syndrome using a composition containing a pharmaceutically effective amount of a gastric inhibitory polypeptide (GIP) molecular antagonist, as well as a method for reducing adipose tissue accumulation in the liver, reducing adipose tissue accumulation in the omentum or reducing the accumulation of the subcutaneous fat tissue using the composition containing a pharmaceutically effective amount of the molecular GIP antagonist. Also disclosed is a molecular GIP antagonist. Molecular GIP antagonist comprises a light chain variable domain and a heavy chain variable domain, where the variable light chain domain has 100 % identity with the amino acid sequence SEQ ID NO: 17, SEQ ID NO: 18 or SEQ ID NO: 19, and the heavy chain variable domain has 100 % identity with the amino acid sequence SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30.
EFFECT: group of inventions provides reduced rate of weight gain, low synthesis and accumulation of lipids.
19 cl, 19 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
| COMPOSITIONS AND METHODS FOR INCREASING BODY WEIGHT AND LEAN MUSCLE MASS USING LEPTIN RECEPTOR ANTAGONISTS, GDF8 AND ACTIVIN A | 2019 |
|
RU2818832C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
